Could a heart pill beat long COVID fatigue? new trial aims to find out.
NCT ID NCT05697640
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the drug vericiguat, already approved for heart failure, can improve physical function and reduce fatigue in people aged 18-50 with post-COVID syndrome. About 104 participants will receive either vericiguat or a placebo for 10 weeks, then be followed for 30 days. The goal is to see if the drug helps with daily activities like walking and carrying groceries.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POST-COVID-19 SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Charité - Universitätsmedizin Berlin
Berlin, State of Berlin, 10117, Germany